Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Alnylam

Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ALNY has a 100% technical “Buy” opinion via Barchart. The company boasts a robust pipeline, recent FDA approvals, and dramatic projected revenue and earnings growth for 2025. Analyst sentiment is mostly bullish with high price targets....

Barchart

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported upbeat second-quarter earnings and 2025 guidance on Thursday.

Benzinga

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam’s recent performance highlights the company’s strong position in the competitive landscape.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio

Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.

Investors Business Daily

Biotech Eyes Early Entry As Several Factors Could Unleash Shares

Alnylam stock is in flat base and is offering a potential early entry. The biopharma company is hosting its Investor Day as earnings loom.

Investors Business Daily

Why IBD 50's Alnylam Just Reversed Its 50% Gain — And BridgeBio Surged

Alnylam stock tumbled Friday after the company's Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study.

Investors Business Daily

Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug

Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Alnylam Is Now 'One Of The Most Binary' Stories In Biotech. Why The FDA Rejected Its Heart Drug.

Alnylam stock skidded Monday after the FDA rejected its drug, Onpattro, as a treatment for patients with a heart disease.

Investors Business Daily

Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer

Alnylam stock tumbled Thursday after a split advisory panel recommended the Food and Drug Administration approve its heart disease treatment.

Investors Business Daily

BridgeBio Launches 76% And Pulls Its Rival Higher On Bullish Heart Drug News

BridgeBio landed a "best-case scenario" for its heart-disease drug on Monday, helping BBIO stock and shares of one of its competitors to rocket.

Investors Business Daily

Intellia, Other CRISPR Stocks Hammered On Safety Concerns In New Gene-Editing Test

Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.

Investors Business Daily

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Benzinga

Something Unusual Is Happening Right Now With Biotech Stocks

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

Investors Business Daily

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug

Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned

A gene-editing treatment from Intellia led to elevated liver enzymes in one patient with polyneuropathy, prodding NTLA stock to topple.

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Benzinga

Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Investors Business Daily

Alnylam Pharmaceuticals Scores 'Clean Hit' In Closely Watched Heart Study, And Hits A Record

Alnylam stock hit a record high Wednesday after the company reported a "clean hit" for its Pfizer rival cardiomyopathy drug.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Alnylam's Stock Gains Following FDA Nod For hATTR Amyloidosis Candidate

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ (NASDAQ: ALNY) lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

Benzinga

What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals

Morgan Stanley downgraded its rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) to Equal-Weight with a price target of $178.00, changing its price target from $210.00 to $178.00. Shares of Alnylam Pharmaceuticals are trading down 4.47% over the last 24 hours, at $159.53 per share.

Benzinga

See Why Did FDA Extend Review Period For Alnylam's Vutrisiran In Amyloidosis

The FDA has extended the review timeline for Alnylam Pharmaceuticals Inc's (NASDAQ:ALNY) marketing application for vutrisiran for transthyretin-mediated (ATTR) amyloidosis. The updated Prescription Drug User Fee Act (PDUFA) goal date is July 14. The FDA needs additional time to review newly added information related to the new secondary packaging and labeling facility for investigational RNAi…

Benzinga

Alnylam Hits Pfizer, Moderna With Patent Infringement Suits

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) has filed separate lawsuits in the Delaware federal court against Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA), seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines. Alnylam said it was seeking compensation for the use of its lipid nanoparticles (LNP) technology that carries and delivers…

Benzinga

Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B

Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY)

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Food and Drug Administration

the Food and Drug Administration

196 stories

MRNA

194 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.